MCL coexpression mm9:810
From FANTOM5_SSTAR
Phase1 CAGE Peaks
Short description | |
---|---|
Mm9::chr12:85379338..85379385,+ | p1@Acot4 |
Mm9::chr18:61879449..61879487,- | p@chr18:61879449..61879487 - |
Mm9::chr19:10678794..10678805,- | p4@Dak |
Mm9::chr2:155418444..155418506,- | p1@Gss |
Mm9::chr2:163367451..163367464,- | p1@0610008F07Rik |
Mm9::chr2:163372869..163372882,+ | p3@Hnf4a |
Mm9::chr2:163372884..163372904,+ | p1@Hnf4a |
Mm9::chr3:94176733..94176794,+ | p1@Rorc |
Mm9::chr6:43616157..43616223,- | p1@Tpk1 |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0006732 | coenzyme metabolic process | 0.00158271079552393 |
GO:0051186 | cofactor metabolic process | 0.00158271079552393 |
GO:0003707 | steroid hormone receptor activity | 0.00385919243044701 |
GO:0004879 | ligand-dependent nuclear receptor activity | 0.00385919243044701 |
GO:0009108 | coenzyme biosynthetic process | 0.00457210022760891 |
GO:0042357 | thiamin diphosphate metabolic process | 0.00457210022760891 |
GO:0004363 | glutathione synthase activity | 0.00457210022760891 |
GO:0009229 | thiamin diphosphate biosynthetic process | 0.00457210022760891 |
GO:0004371 | glycerone kinase activity | 0.00457210022760891 |
GO:0042724 | thiamin and derivative biosynthetic process | 0.00457210022760891 |
GO:0004788 | thiamin diphosphokinase activity | 0.00457210022760891 |
GO:0051188 | cofactor biosynthetic process | 0.00516392620901728 |
GO:0006772 | thiamin metabolic process | 0.00670482850567052 |
GO:0048537 | mucosal-associated lymphoid tissue development | 0.00670482850567052 |
GO:0042723 | thiamin and derivative metabolic process | 0.00670482850567052 |
GO:0006104 | succinyl-CoA metabolic process | 0.00887282225080137 |
GO:0046459 | short-chain fatty acid metabolic process | 0.00887282225080137 |
GO:0044237 | cellular metabolic process | 0.012659751575851 |
GO:0006750 | glutathione biosynthetic process | 0.0158711586352915 |
GO:0016778 | diphosphotransferase activity | 0.0175881248661717 |
GO:0043648 | dicarboxylic acid metabolic process | 0.0215305804242013 |
GO:0016290 | palmitoyl-CoA hydrolase activity | 0.0251121303351356 |
GO:0006637 | acyl-CoA metabolic process | 0.0271973565350132 |
GO:0016291 | acyl-CoA thioesterase activity | 0.0271973565350132 |
GO:0016439 | tRNA-pseudouridine synthase activity | 0.0280890825215545 |
GO:0006100 | tricarboxylic acid cycle intermediate metabolic process | 0.0280890825215545 |
GO:0016289 | CoA hydrolase activity | 0.0280890825215545 |
GO:0005524 | ATP binding | 0.0280890825215545 |
GO:0032559 | adenyl ribonucleotide binding | 0.0280890825215545 |
GO:0048535 | lymph node development | 0.0280890825215545 |
GO:0009982 | pseudouridine synthase activity | 0.0280890825215545 |
GO:0006071 | glycerol metabolic process | 0.0280890825215545 |
GO:0006749 | glutathione metabolic process | 0.0280890825215545 |
GO:0030554 | adenyl nucleotide binding | 0.0280890825215545 |
GO:0019751 | polyol metabolic process | 0.0286642222772942 |
GO:0046632 | alpha-beta T cell differentiation | 0.0292573863030531 |
GO:0043565 | sequence-specific DNA binding | 0.0319626946343949 |
GO:0033077 | T cell differentiation in the thymus | 0.0329789809096057 |
GO:0016866 | intramolecular transferase activity | 0.0361091449643436 |
GO:0044272 | sulfur compound biosynthetic process | 0.0361091449643436 |
GO:0032553 | ribonucleotide binding | 0.0361091449643436 |
GO:0032555 | purine ribonucleotide binding | 0.0361091449643436 |
GO:0046631 | alpha-beta T cell activation | 0.0361091449643436 |
GO:0017076 | purine nucleotide binding | 0.039258165142745 |
GO:0006767 | water-soluble vitamin metabolic process | 0.0433610996112219 |
GO:0006629 | lipid metabolic process | 0.0464976064349754 |
GO:0005496 | steroid binding | 0.0499772616505179 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |